The GALK1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte line, engineered to disrupt the GALK1 gene. This heterogeneous population provides a loss-of-function model for studying galactokinase deficiency in a B-cell malignancy context. The knockout was generated via CRISPR/Cas9-mediated gene disruption, eliminating GALK1 expression and abolishing its enzymatic activity without specifying the exact editing outcome.
Raji cells are an immortalized B lymphocyte line originally isolated from a Burkitt??s lymphoma patient and are Epstein-Barr virus (EBV)-positive. Widely employed in immunology and lymphoma research, Raji cells serve as a robust model for investigating B-cell receptor signaling, apoptosis, and oncogenic pathways. Their rapid proliferation and well-characterized background make them an ideal host for gene-editing studies, enabling reproducible and scalable functional assays in hematopoietic malignancy research.
GALK1 encodes galactokinase, which catalyzes the ATP-dependent phosphorylation of galactose to galactose-1-phosphate, the first committed step in the Leloir pathway of galactose metabolism. This enzyme functions in concert with galactose mutarotase (GALM), galactose-1-phosphate uridylyltransferase (GALT), and UDP-galactose 4??-epimerase (GALE). Galactokinase activity requires Mg2+ as a cofactor, and its product, galactose-1-phosphate, is subsequently converted by GALT and GALE to UDP-galactose, a critical precursor for glycosylation. Disruption of GALK1 blocks this metabolic flux, leading to the accumulation of galactose and its alternative metabolite galactitol, which can induce osmotic stress and toxicity.
In the Raji B-cell context, GALK1 knockout allows the dissection of galactose metabolism??s role in lymphocyte physiology and cancer. Aberrant glycosylation is a hallmark of many malignancies, and UDP-galactose availability directly influences glycoconjugate biosynthesis. By eliminating galactokinase activity, this model enables investigation of how impaired Leloir pathway function affects B-cell glycosylation profiles, proliferation, and survival. Additionally, the EBV-positive background of Raji cells offers a unique platform to explore intersections between viral latency, metabolic reprogramming, and galactose utilization, potentially uncovering vulnerabilities in lymphoma cells.
These polyclonal knockout cells are suitable for a range of applications including galactosemia type II disease modeling, galactose toxicity assays, and functional analyses of Leloir pathway disruption in B-cell malignancies. Researchers can assess knockout efficiency by Western blot for GALK1 protein, RT-qPCR for GALK1 mRNA, or galactokinase activity assays. Downstream studies may involve cell viability measurements under galactose challenge, quantification of galactose-1-phosphate, metabolomic profiling of galactose and galactitol, and lectin-based glycosylation analysis. Flow cytometry can monitor apoptosis or proliferation under varying metabolic conditions. This product also supports drug screening efforts targeting galactose metabolism or compensatory pathways. For further details or to place an order, please contact Ascent Research.
